ODTC

Odonate Therapeutics, Inc. [ODTC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ODTC Stock Summary

In the News

ODTC Financial details

Company Rating
-
Market Cap
67.36M
Income
-112.49M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
137
Optionable
No
Shortable
Yes
Earnings
08 Nov 2022
P/E
-715.25
Forward P/E
-
PEG
298.71
P/S
-
P/B
663.79
P/C
-
P/FCF
-0.47
Quick Ratio
5.81
Current Ratio
5.91
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.99K
EPS next Y
-
EPS next Q
-
EPS this Y
-2.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
6.49%
-
-
-
-
SMA20
12.73%
SMA50
16.33%
SMA100
16.3%
Inst Own
-
Inst Trans
-
ROA
-75%
ROE
-85%
ROC
-0.9%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.5-49895.0
52W High
+200.63%
52W Low
+2142757.14%
RSI
35.15
Rel Volume
-
Avg Volume
10
Volume
Perf Week
-14.79%
Perf Month
9.97%
Perf Quarter
-
Perf Half Y
9.97%
-
-
-
-
Beta
0.027662
-
-
Volatility
9112.1%, 17905.82%
Prev Close
0%
Price
150000
Change
0%

Something similar

Top by Market Cap
LLY.SW
GOOGL
EMBASSY.NS
3V64.DE
VTSAX
Same Sector
2395.T
LOTUSEYE.NS
ATRI
6826.HK
1521.HK
Same Price Range
272560.KS
002030.KS
114460.KS
039030.KQ
8977.T
Similar Market Cap
8402.HK
AGNG
BEMO
RCLF
XRTX

Company Profile

Healthcare Biotechnology
  • Volume Average 10
  • Market Capitalization 67.36M
  • Employee 137
  • CEO Mr. Kevin C. Tang
  • Headquarters New York,NY,US
  • IPO Date 2017-12-07
  • Website https://www.odonate.com

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.